Sellas Life Sciences is trading 4.2% lower at $9.94, with selling tied to its REGAL trial update and uncertainty ahead of topline results. - The October 28 announcement said the Phase 3 REGAL trial reached its 80th event, triggering final analysis; no efficacy results were disclosed. - Topline results are expected this quarter. The Nasdaq was down 1.78% and the S&P 500 down 0.71% in the supplied market context. - No separate company announcement for October 29 surfaced in the search results.